Drug Approval | October 02, 2024
Aurobindo Pharma receives USFDA approval for Cephalexin Tablets
The product is expected to be launched in Q3FY25
The product is expected to be launched in Q3FY25
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
EDQM has also issued a Certificate of Suitability for Allopurino
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Submission based on results from pivotal phase III trial showing all primary endpoints met
Subscribe To Our Newsletter & Stay Updated
